Symberix, Inc. news

Symberix co-founder Matthew Redinbo gave the keynote address at the AACR Microbiome, Viruses, and Cancer conference on Friday, February 21, 2020. The special conference covers the contribution of bacterial, viral, and fungal pathogens to the development of cancers, as well as the impact of the microbiome on cancer therapy. Dr. Redinbo’s keyn

Symberix has been awarded the Phase II portion of a Small Business Innovation Research (SBIR) Fast-Track grant from the National Institutes of Health (NIH). The NIH Fast-Track application process expedites award decisions and funding of Phase II applications that have a high potential for commercialization by allowing Phase I and Phase II grant applications to be submitted and reviewed together. The $2 million in Phase II grant funding will support preclinical efforts to select and develop a

Symberix, a preclinical stage company dedicated to the development of novel pharmaceutical treatments for lower gastrointestinal (GI) disorders, has been awarded two Small Business Innovation Research (SBIR) grants from the National Institutes of Health (NIH).

The two SBIR grants collectively totaling over $1.5 million are awarded by the NIH’s National Center for Advancing Translational Sciences and National Institute of Diabetes and Digestive and Kidney Diseases. The funded eff

Symberix, a preclinical stage company dedicated to the development of novel pharmaceutical treatments for lower gastrointestinal (GI) disorders, has been awarded three Small Business Innovation Research (SBIR) grants from the National Institutes of Health (NIH), entered into a Research Collaboration Agreement with the NIH’s National Center for Advancing Translational Sciences (NCATS), and received a $250,000 Small Business Research Loan from the North Carolina Biotechnology Center.

Symberix, a pioneer in microbiome-targeted drug discovery, announced today the addition of P. Kay Wagoner, Ph.D. to its Board of Directors, the allowance of broad method-of-treatment claims for an invention licensed to Symberix by University of North Carolina and inclusion as a Portfolio Company in the Blackstone Entrepreneurs Network, a resource for high potential start-up companies.

Dr. Wagoner is a leader and teacher in health care and university education with over 30 years of exp